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ABSTRACT
Interaction with Max via the helix–loop–helix/leucine
zipper (HLH-LZ) domain is essential for Myc to
function as a transcription factor. Myc is commonly
upregulatedintumours,however,itsactivitycanalso
be potentiated by virally derived mutations. vMyc,
derived from the virus, MC29 gag-Myc, differs from
its cellular counterpart by five amino acids. The
N-terminal mutation stabilizes the protein, however,
the significance of the other mutations is not known.
We now show that vMyc can sustain longer deletions
in the LZ domain than cMyc before complete loss in
transforming activity, implicating the viral mutations
in contributing to Myc:Max complex formation. We
confirmed this both in vitro and in vivo, with loss
of Max binding correlating with a loss in the bio-
logical activity of Myc. A specific viral mutation,
isoleucine383.leucine (I383.L) in helix 2 of the HLH
domain, extends the LZ domain from four to five
heptad repeats. Significantly, introduction of I383.L
into a Myc mutant that is defective for Max binding
substantially restored its ability to complex with
Max in vitro and in vivo. We therefore propose that
this virally derived mutation is functional by signific-
antlycontributingtoestablishingamorehydrophobic
interface between the LZs of Myc and Max.
INTRODUCTION
Retrovirally transduced oncogenes have acquired mutations
that considerably potentiate their transforming activity by
subverting their normal regulation in a cell. These mutations
may result in altered regulation of the oncoprotein by key
signalling pathways (e.g. phosphorylation), a reduction or
interference in key protein:protein interactions, altered protein
turnover or a combination of all these. Indeed, comparative
studies between these virally derived oncogenes and their
cellular counterparts have contributed greatly toward our
current understanding of their molecular mechanism of action.
vSrc, the transforming component of Rous sarcoma virus, and
vErbB, isolated from the avian erythroblastosis virus, AEV,
contain several that contribute to their constitutive tyrosine
kinase activity (1,2).
Nuclear oncogenes have also been retrovirally transduced
andsustainedmutationsthatpotentiatetheirtransformingactiv-
ity (3–5). Retrovirally transduced cJun and cFos, the two com-
ponents of the AP-1 transcription factor complex, have
sustained mutations which abrogate key phosphorylation
eventsandcontributetoanincreasedhalfliferespectively(3,4).
cMyc, the transforming component of the avian leukosis
virus, MC29, belongs to the basic/helix–loop–helix/leucine
zipper (b-HLH-LZ) class of transcription factors (6). Somatic
and virally derived point mutations in Myc potentiate its
function as an oncoprotein, the majority of which are clustered
within the transactivation domain at the N-terminus of the
protein (7–10). Of the ﬁve mutations in MC29 vMyc (11),
a functional consequence has only been attributed to threonine
61.This mutation,threonine61>methionine(T61>M)whichisa
known phosphorylation site (12), results in signiﬁcant stabil-
ization of the Myc protein (7,13,14).
Myc functions in association with a small unrelated protein,
Max, dimerizing through the C-terminal HLH-LZ domain.
Dimerization with Max is not, however, sufﬁcient for Myc
to function, since the complex must also be able to bind to a
speciﬁc target DNA sequence and activate transcription
through its N-terminus (6). The LZ domains of Myc and
Max form a parallel two-stranded a-helical coil and dictate
the speciﬁcity of heterodimerization (15). A detailed sequence
comparison between the LZs of different transcription factors
shows that in contrast to Fos and Jun which each contain ﬁve
leucine residues in a heptad repeat (denoted L1–L5 in
Figure 1), cMyc contains only four (denoted L2–L5 in
Figure 1). Strikingly, in MC29 vMyc, mutation of isoleucine
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doi:10.1093/nar/gki832to a leucine at position 383 (Figure 1) extends the cMyc LZ to
ﬁveleucine residuesinaheptadrepeat. Thisled ustospeculate
that by increasing the length of the LZ, this virally derived
mutation may contribute positively to the interaction with
Max. The data we present in this manuscript is consistent
with this and for the ﬁrst time, we propose a functional
consequence of this virally derived mutation in the C-
terminus of vMyc.
MATERIALS AND METHODS
Cell culture and transfections
Cell culture and transfection of appropriate SFCV-Myc con-
structs (10 mg) together with RCAN (A) helper (4 mg) into
secondary chick embryo ﬁbroblasts (CEFs) was performed
essentially as described (16). Following G418 selection, cul-
tures were expanded and used to analyse alterations in cell
behaviour which was mediated by overexpression of the Myc
oncoprotein (16). Brieﬂy, anchorage independent growth was
determinedbyplating2 · 10
5cellsinto0.35%agarandincub-
ated at 41 C for 2 weeks prior to photography. Growth rate
was measured by plating 2 · 10
5 cells in a 35 mm diameter
dish, and cumulative cell counts performed each day.
Construction of retroviral vectors expressing mutant
Myc alleles
The construction of SFCV-cMyc and SFCV-vMyc has been
described (17). All the LZ mutants of vMyc were generated by
site directed mutagenesis as described (18) using mp8-vMyc
as the template. The mutagenic oligonucleotides were as
follows: vMycD7, 50-aaccttgagtagctaaggaag-30; vMycD10,
50-agttgaaacactaacttgagc-30 and vMycD14, 50-gtgtttcaac-
tattctctcctccgcctcaa-30. To generate the isoleucine383>leucine
leucine (I383>L) mutant, mutagenesis was performed using
the primer 50 gttctgtctccaatcggacgag 30. To generate the
I383>LD10 mutant, mutagenesis was performed on the
I383>L template using the primer 50-gttgaaacactaacttgagc-30.
The underscored nucleotides encode the mutant amino acid.
The resulting mutants were retrieved from mp8 and cloned
as HindIII fragments into SFCV-sa
  (17) and pSPT19 (19).
All mutant sequences were conﬁrmed by double stranded
sequencing.
Western blot analysis
Cell lysates were prepared by lysing cultures in SDS-sample
buffer(20).Followingsonicationandproteinestimation,50mg
protein was loaded onto 7.5% SDS–PAGE gels. Transfer to
nitrocellulose and western blotting was performed as
described (18). Proteins were detected using speciﬁc rabbit
antibodies [anti-cMyc antibody, 237 (19) and anti-Max
antibodies (21)] and visualized using either NBT/BCIP
(anti-cMyc 237) or enhanced chemiluminescence (anti-Max).
In vitro translation of Myc and Max proteins and
immunoprecipitation
Dimerization between Myc and Max was determined using
[
35S]methionine-labelled in vitro translated proteins essen-
tially as described (19). Brieﬂy, following incubation with
Myc proteins, Max or Max9 were speciﬁcally immunoprecip-
itated using an anti-cMyc antibody, 237. The immune com-
plexes were recovered on protein A–Sepharose beads, washed
thoroughly and resolved on 10% SDS–PAGE gels. The
[
35S]methionine labelled proteins were detected by ﬂuoro-
graphy using Amplify (Amersham).
Reporter and activator plasmids
The PHO5 UAS-CYC-LacZ reporter plasmid, pRS314-Max/
Max9, PHO4-cMyc (Pho4-cMyc) and Pho4 cMyc LZ mutant
hybridshave beendescribedpreviously(19).ThePHO4-vMyc
(Pho4-vMyc), Pho4 vMyc LZ mutants and Pho4-I>LD10
hybrids were made by PCR of the appropriate templates
and were cloned into the BglII site of pMA132 (19).
The integrity of all expression constructs was veriﬁed by
sequencing.
The Pho5 UAS-CYC-Lac Z reporter plasmid encodes the
Pho4 DNA-binding sequence upstream of b-galactosidase.
This sequence, CACGTG, has also been shown to be a
Figure 1. Sequence alignment of the LZ domains of different transcription factors. The amino acids that correspond to position 7 in a heptad repeat are boxed. The
leucine repeats are indicated below, with leucine 1 (L1) and leucine 5 (L5) being the most N-terminal and C-terminal of the heptad repeats, respectively. Sequences
were taken from the following accession numbers: human cMyc (NM_002467), murine cMyc (NM_010849), feline cMyc (M22727), avian cMyc (J00889), avian
MC29 vMyc (VO1173), avian MH2 vMyc (K02082), human Nmyc (NM_005378), murine Nmyc (NM_008709), human Max (NM_002382), human cJun
(NM_002228), human cFos (BC004490) and human C/EBP (NM_005194).
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Pho4-Myc plasmids express the Pho4 transactivation domain
fused to the b-HLH-LZ domain (amino acids 327–415) of the
different Myc isoforms. pRS315-Max/Max9 expresses the two
different Max isoforms.
Dimerization between the b-HLH-LZ domains of Myc and
Max was detected by transforming the above plasmids into
yeast. The Pho4–Myc/Max complexes formed in vivo will
bind to the Pho5 UAS-CYC consensus sequence upstream
of the LacZ gene. Transcription of LacZ will then be
initiated by the Pho4 transactivation domain. The level of
b-galactosidase activity in cell lysates of the transformants
will therefore be a direct measure of the extent of dimerization
between the b-HLH-LZ domains of Myc and Max (19).
The construction of pGV256-lex-OP was as described (23).
To generate pRS315-lex-Max9, the Max 9 coding sequence
was ﬁrst inserted as a BglII fragment into pV44ER-lex (23).
The entire cassette comprising the GAL UAS, CYC promoter,
Lex-Max9 and the CYC terminator was then cloned as an
Sst1–Kpn1 fragment into pRS315.
These plasmids were used in an alternate dimerization assay
that independently measures Myc/Max complex formation.
pGV256-lex-OP contains the Lex operator upstream of
CYC-LacZ (23). Lex A, the bacterial repressor, binds to the
Lex operator. pRS315-lexA-Max 9 encodes a fusion protein
between the bacterial Lex A repressor and Max 9, which will
bind to the Lex operator. These plasmids were then trans-
formed into yeast along with Pho4-Myc. Any Lex A-
Max9:Pho4-Myc complexes that are formed will bind to the
Lex operator sequence via LexA-Max9. The b-galactosidase
activity that is detected in the transformants will be the direct
result of the complex formation between LexA-Max 9 and
Pho4-Myc,since thePho4transactivation domain will mediate
transcriptional activation. This assay therefore provides a
dimerization assay which is independent of DNA binding
mediated by the Myc:Max complex.
Yeast culture and b-galactosidase assays
Reporter assays were performed in the yeast strain Y700 (a,
his3–11, ade2–1, leu2–3,  112, ura3, trp1–1 and can1–100)
essentially as described (19). Following selection on yeast
glucose minimal agar plates supplemented with the appro-
priate amino acids, the transformants were grown in liquid
culture and b-galactosidase activity measured (22). Activities
represent the average of at least two independent dupli-
cate cultures within the same experiment and units of b-
galactosidase activity were calculated as described (19).
RESULTS
vMyc can sustain longer truncations in its LZ domain
than cMyc before loss of biological activity
Previous work from our laboratory showed that the integrity of
the LZ domain was essential for Myc to function (18). Dele-
tion of seven amino acids (removal of L5) in cMyc resulted in
a mutant, cMycD7, which retained partial transforming activ-
ity (18). Deletion of a further three amino acids (removal of
L4a and L5), however, resulted in a non-transforming mutant
of Myc, cMycD10. We reasoned that vMyc might be able to
sustain longer truncations in the LZ domain than cMyc before
complete loss of biological activity. To address this, we gen-
erated a series of point mutants of vMyc which successively
truncated leucine residues from the C-terminus. These
mutants, designated vMycD7, vMycD10 and vMycD14,
were cloned into avian retroviral vector, SFCV-sa
  (24)
and transfected into CEF. It should be noted that these con-
structs only encode the vMyc portion of MC29, and not the
p110 gag-Myc encoded by the original MC29 virus (25). Fol-
lowing G418 selection, expression of all Myc-containing con-
structs was conﬁrmed by western blot analysis (Figure 2). All
were expressed in CEF, although the vMycD14 and cMycD14
Figure 2. LZ mutants of MC29 vMyc and avian cMyc. (A) Schematic repre-
sentation showing location of MC29 vMyc mutations. Five mutations are con-
tained within MC29 vMyc (11). These are found in the transactivation domain
(T61>M), adjacent to the basic region (B) (serine325>leucine—S325>L), within
helix 1 (serine350>arginine—S350>R) and helix 2 (I383>L) of the HLH domain,
and within the LZ domain (lysine407>arginine—K407>R). LZ deletion mutants
of MC29 vMyc and avian cMyc are shown.The leucine repeats(L1–L5) within
theLZsofMC29vMycandaviancMycarealsoindicated.LeucineL4aisshown
offset to indicate its internal location (position 3) within the most C-terminal
heptad repeat. Premature translation termination codons (indicated by an
asterisk) were introduced into MC29 v-myc and avian c-myc (18) by site-
directed mutagenesis. The D7 and D14 mutants truncate specifically at L5
and L4 within the heptad, respectively, whilst the D10 truncation removes L5
and L4a.( B) Retrovirally-expressed cMyc, vMyc and their respective LZ
mutants in CEFs were detected by western blot of total cell lysates using an
anti-Myc antibody(upper panel). Equivalenceof loadingwas shownby Max9,
themainisoformofMaxinCEF(17,26),whichwasdetectedusingananti-Max
antibody (21) (lower panel). Vector control is shown by a dash.
Nucleic Acids Research, 2005, Vol. 33, No. 16 5237mutants did appear to be expressed at lower levels than the
wild-type. These low levels were unexpected. These mutants
should bind Miz-1, but not Max (Figures 4 and 5). Since the
former stabilizes Myc, and the latter has no affect on its half
life(13),we wouldexpect at least equal levels of the vMycD14
and cMycD14 mutants. Chicken Miz-1 has not, however, been
characterized, and its levels in CEF are not known. The sig-
niﬁcance of the reduced expression of these two mutants is
therefore not known. The level of Max9, the major Max
isoform in CEF (17,26), does not change in the Myc-
infected cells (Figure 2B).
CEF which overexpress Myc undergo extensive changes in
cell morphology, grow more rapidly and acquire the ability to
grow in an anchorage independent manner (16,18). Therefore,
having conﬁrmed the appropriate retroviral expression, we
determined changes in cell morphology (Figure 3A), calcu-
lated the growth rate (Figure 3B) and determined the ability to
grow in agar of CEF overexpressing each Myc mutant (16,18).
Figure 3. vMyc can sustain longer deletions in the LZ than cMyc before loss of biological activity (A) Cell morphology of CEF expressing cMyc, vMyc and their
respectiveLZmutantsareshown.(a)cMyc,(b)cMycD7,(c)cMycD10,(d)cMycD14,(e)vMyc,(f)vMycD7,(g)vMycD10,(h)vMycD14and(i)vectorcontrol.(B)
Growth rate of CEF expressing cMyc, vMyc and their respective LZ mutants. Growth rate was measured by cumulative cell counts over 4 days. These data are
representative of at least two different experiments. (C) The ability of retrovirally-expressed cMyc, vMyc and their respective LZ mutants to induce anchorage-
independentgrowthwasdeterminedbyplatinginfectedCEFintosoftagar.Colonycountsweretakenafter14days.Vectorcontrolisshownbyadash.Thesedataare
representative of at least two different experiments.
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contact inhibited, lining up in a parallel manner on the dish
(Figure 3A, i). In contrast, cMyc-infected CEF are rounder,
more refractile and do not undergo contact inhibition
(Figure 3A, a). cMycD7 (Figure 3A, b) had an intermediate
phenotype, being partially morphologically-transformed.
Deletion of 10 amino acids or more from the cMyc LZ,
however, resulted in mutants that were non-transforming
(Figure 3A, c and d). vMyc (Figure 3A, e) was more highly
transformed than cMyc (Figure 3A, a), highlighting a major
role for the viral mutations in potentiating the biological
activity of Myc (9). vMyc (Figure 3A, e) and vMycD7
(Figure 3A, f) were morphologically indistinguishable from
eachotherandwerehighlytransformed.vMycD10(Figure3A,
g) was partially transformed, however, vMycD14 (Figure 3A,
h) was non-transformed. Thus, deletion of 14 amino acids
from the vMyc LZ was required before loss in biological
activity, whilst deletion of only 10 amino acids was required
before cMyc became functionally inert. These data clearly
show that vMyc can sustain longer truncations in its LZ
than cMyc before loss of morphological transformation.
Another feature of Myc-transformed cells is an accelera-
ted cell growth (18). The growth rate of Myc-infected
CEF, determined by cumulative cell counts >4 days, is
shown graphically (Figure 3B). As previously reported,
cMyc and cMycD7 have accelerated growth rates, but fur-
ther truncation of the LZ domain resulted in growth rates
comparable with uninfected CEF (18). In contrast, vMyc,
vMycD7 and vMycD10 grew more rapidly than control
cells, whilst vMycD14 was indistinguishable from the
control.
Loss of anchorage dependence by transformed cells was
measured by the ability to grow in soft agar. Myc-infected
CEF were plated in agar and after 2 weeks, plates were pho-
tographed. A minimum of eight frames were taken for each
and the average number of colonies calculated (Figure 3C). It
can clearly be seen that in contrast to vMycD7, cMycD7 only
partially retains the ability to grow in agar. In contrast to
cMycD10, vMycD10 was however still partially able to
grow in agar.
Collectively, these data show that the integrity of the LZ
domains of vMyc and cMyc are required for biological activ-
ity. More importantly, these results highlight a major func-
tional difference in the behaviour of the vMyc and cMyc LZ
domains, since vMyc can sustain longer truncations than cMyc
before complete loss in its biological activity (Table 1).
Indeed, deletion of 10 amino acids from the C-terminus of
vMyc results in a mutant that still retains biological activity,
whilst deletion of 10 amino acids from cMyc results in a
mutant that is functionally inactive. This difference in the
behaviour of the LZ domains must be a direct consequence
of the virally derived mutations.
BiologicallyactiveLZmutantsofvMycretaintheability
to dimerize with Max in vitro and in vivo
Since Myc requires Max to function (27), we set out to estab-
lish whether the vMyc LZ mutants retained the ability to
dimerize with Max. [
35S]-labelled Myc and Max were pro-
duced in an in vitro translation system, and Myc–Max com-
plexes allowed to form at 37 C. Complexes were recovered by
immunoprecipitation using an anti-Myc antibody that does not
recognize Max (Figure 4). The central lane in both panels,
indicated by a dash, contained Max or Max9 alone demon-
strating that the Myc antibody does not immunoprecipitate
Max. From these data, it can be seen that in contrast to
vMyc, vMycD7 and vMycD10 which can complex with
Max (upper panel) and Max9 (lower panel), only cMyc and
cMycD7complex with Max.Therefore,thesedataconﬁrm that









cMyc D7± ± + ±
cMyc D10      
cMyc D14      
vMyc ++ ++ + +
vMyc D7 ++ ++ + +
vMyc D10 ± ± + ±
vMyc D14      
vMyc can sustain longer truncations in its LZ before loss in biological activity
andbindingto Max.Summaryofthe biologicalactivityofLZ mutantsofavian
cMycandvMycexpressedinCEFs.vMyccansustainlongerdeletionsoftheLZ
before complete loss in biological activity. Like cMycD7, vMycD10 retains
partial biological activity, whilst cMycD10 is biologically inactive.
Figure4.ComplexformationbetweenMax/Max9andtheLZmutantsofv-and
c-Myc in vitro. cMyc, vMyc, LZ mutants and Max/Max9 were produced in
rabbit reticulocyte lysate and Myc/Max complex formation determined by
immunoprecipitation of Max using an anti-myc specific antibody. [
35S]-
labelledproteinswereresolvedbySDS–PAGEandvisualizedbyfluorography.
Central lane was Max/Max9 alone.
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cMyc before losing the ability to complex with Max. Import-
antly, all the transforming mutants of both vMyc and cMyc
(Figure 3) bound to Max and Max9.
To conﬁrm these data, we tested the ability of the LZ
mutants of Myc to complex with Max in vivo using a yeast
assay designed to measure dimerization and DNA binding of
Myc:Max complexes. This assay has been used previously as
a reliable and sensitive assay for Myc:Max function in vivo
(19,28). In this assay, the bHLH-LZ domain of avian Myc
or vMyc (amino acids 330–417) or their respective LZ
mutants, were fused to the transactivation domain of the
yeast transcription factor Pho4. When Pho4-Myc was trans-
fected into yeast together with a PHO5 UAS-CYC-lacZ
reporter plasmid, transcription through the PHO5-UAS
occurred only in the presence of Max or Max9 (19). As expec-
ted, only Pho4-cMyc and Pho4-cMycD7 were able to activate
transcription, whilst Pho4-cMycD10 and Pho4-cMycD14 did
not. In contrast to cMyc, co-expression of Max or Max9 with
Pho4-vMyc, Pho4-vMycD7 and Pho4-vMycD10 activated
transcription through the PHO5-UAS, albeit at a reduced
level for Pho4-vMycD10 (Figure 5A). These in vivo data con-
ﬁrm the in vitro results (Figure 4) clearly showing that vMyc
can sustain a larger truncation to the LZ domain than cMyc
before losing the ability to bind to Max.
As an independent measure of dimerization, we used an
assay which asks whether Myc function was mediated by
direct complex formation with Max, independently of its
DNA binding activity. To achieve this, we fused the bacterial
protein, LexA, to Max9, generating pRS315-lexA-Max9.
When transfected into yeast, LexA binds to a speciﬁc DNA
sequence, LexOP, which lies upstream of b-galactosidase,
however, no b-galactosidase activity will be detected in the
absence of Pho4-Myc. As expected, no activity was detected
when pRS315-lexA-Max9 was transfected into yeast along
with pGV256-lex-OP (23). When they were co-transfected
with Pho4-Myc plasmids, however, b-galactosidase activity
was recorded. As can be seen from Figure 5B, signiﬁcant
b-galactosidaseactivitywasrecordedwithallthetransforming
mutants of cMyc and vMyc.
Collectively, these data (Figures 4 and 5) clearly show that
the LZ domains of vMyc and cMyc differ signiﬁcantly in their
ability to bind to Max both in vitro and in vivo.
Mutation of I383>L in cMycD10 background partially
restores binding to Max in vitro and in vivo
cMycD10 does not bind Max/Max9 (19) (Figures 4 and 5).
Theoretically, the I383>L mutation of vMyc could extend
the LZ domain from four to ﬁve heptad repeats and stabilize
the Myc/Max interaction (Figure 1). To directly test this, we
introduced this mutation into a cMycD10 background. This
mutant, cMycI>LD10 (Figure 6A) was tested for the ability to
complex with Max both in vitro (Figure 6B) and in vivo
(Figure 6C). In both these assays, replacement of isoleucine
383 with a leucine signiﬁcantly restored binding to both Max
and Max9. This mutant did not, however, signiﬁcantly induce
a biological phenotype when overexpressed in CEF,
suggesting that the levels of cMycI>LD10:Max complex
may be below the threshold required to mediate a biological
response. These data do, however, show that this single
mutation is sufﬁcient to contribute positively to the interaction
of Myc and Max.
DISCUSSION
Somatic or virally derived mutations that potentiate the func-
tion of a protein can be viewed as naturally occurring protein
engineering. Currently, many examples of these exist, which
can result in proteins with altered properties, such as different
half lives, differential responses to signalling pathways
Figure5.ComplexformationbetweenMax/Max9andtheLZmutantsofv-and
c-Myc in yeast. Two different experimental systems based on sensitive yeast
two hybrid assays were used to measure complex formation in vivo.( A) Max/
Max9-dependent dimerization and DNA binding were determined in vivo.
b-Galactosidase activity was quantitatively measured as a result of transcrip-
tional activation resulting from the co-transfection of Pho4-cMyc, Pho4-vMyc
or their respective LZ mutants into yeast, together with the PHO5 UAS-CYC-
LacZ reporter. This assay has been shown previously to a reliable assay for
Myc/Max complex formation (28). (B) Dimerization which is independent of
Myc/Max DNA binding was measured by co-transfecting Pho4-cMyc, Pho4-
vMyc or their respective LZ mutants into yeast, along with the reporter,
pGV256-lex-OP (23) and pRS315-lexA-Max9. b-Galactosidase activity was
then determined.
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interactions. In the data presented here, viral mutations clearly
enhance the Max binding properties of the b-HLH-LZ domain,
since the vMyc LZ can tolerate greater loss of its dimerization
interface than cMyc before loss of Max binding.
We propose that the I383>L mutation in MC29 vMyc rep-
resents an example of naturally occurring protein engineering.
Given that HLH-LZ heterodimers are stabilized by hydro-
phobic and polar interactions involving the a-helices, H1,
H2 and LZ (29), the function of the I383>L mutation in the
C-terminus of vMyc would be to contribute to establishing a
more hydrophobic interface which stabilizes the Myc–Max
complex.
Our data are wholly consistent with this proposal, since the
introduction of a single amino acid change, I383>L, into
cMycD10, a LZ mutant which is defective for Max binding,
couldsigniﬁcantly restore itsabilitytocomplex with Maxboth
in vitro and in vivo. This amino acid substitution did not,
however, restore biological activity, although small colonies
were detected in agar (data not shown). Therefore, although
this mutation contributed positively to the Myc:Max interac-
tion, it is most likely that the levels of cMyc I> LD10:Max
complexes formed in CEF were below the threshold required
to elicit any biological response (17).
The I383>L mutation is located in the C-terminal HLH
domain, a region which is known to bind other proteins
(30). This mutation may therefore regulate the interaction
of Myc with these factors. This is thought highly unlikely
given the extremely tight correlation between the ability of
the different LZ mutants to bind to Max and transform cells,
suggesting that it is the Myc:Max complex which is regulated
by these mutations (19,27).
The behavioural differences between the respective LZ
mutants of vMyc and cMyc clearly show that the virally
derived mutations in vMyc impinge on the structure and func-
tion of its b-HLH-LZ domain. Whilst the integrity of the LZ
domain of vMyc was still required for its biological activity,
the v- and cMyc LZ mutants differ signiﬁcantly with respect to
both their biological activity and their ability to bind to Max
(Figures 3–5). Given that the vMyc LZ can tolerate larger
truncations from its LZ zipper domain than cMyc before
loss in its biological activity and binding to Max, this must
reﬂect a stronger interaction between the LZ domains of vMyc
and Max than the LZ domains of cMyc and Max.
These ﬁndings could have major implications in the rational
design of peptide inhibitors for cancer treatment, since a
knowledge of the avidity of protein:protein interactions medi-
ated through HLH-LZ dimerization could dictate the design of
peptide inhibitors for use in a therapeutic context. Indeed, one
such strategy was recently described which was based on the
use of helix 1 (H1) peptides to inhibit the protein:protein
interactions between Myc and Max resulting in a block to
Myc-mediated cell proliferation (31). Although this study
focussed on H1 rather than LZ peptides to block Myc function,
it highlights the general applicability of targeting any essential
dimerization interface with a view to inhibiting function. Our
data couldthereforehave important implicationsifthe targetis
a cancer cell which contains a mutated Myc that has a stronger
dimerization interface than the wild-type Myc, since thera-
peutic targeting of this interface with a relatively weak peptide
inhibitor would obviously be counterproductive.
Conversely, the stability of LZ interactions could be
exploited to therapeutically intervene with Myc:Max com-
plexes in cancer cells. An example of this was described by
Jean-Francois et al. (29), who introduced two point mutations
in Max, His82>Leu and Asn78>Val, with a view to increasing
the hydrophobic interface between the two contributing Max
monomers. This situation is similar to that described here,
since the His82>Leu mutation increased the number of heptad
repeats in the LZ from three to four. Their rationale was that
the stabilized mutant Max homodimers would compete with
Myc:Max heterodimers, block their binding to target E-boxes
Figure 6. I383>Lmutationin cMycD10partiallyrestoresinteractionwithMax/
Max9invitroandinvivo.(A)SchematicrepresentationofcMyc,cMycD10and
cMycI>LD10 mutants. I383>L mutation was introduced into cMycD10, which
does not bind to Max (18). (B) Complex formation between Max/Max9 and
cMyc, cMycD10, and cMyc I>LD10 co-translated in vitro was determined by
immunoprecipitation of Max/Max9 using an anti-Myc antibody, and [
35S]-
labelled proteins resolved by SDS–PAGE and visualized by fluorography.
(C) Complex formation between Max/Max9 and Pho4-cMyc, Pho4cMycD10
and Pho4-cMycI>LD10 was measured in vivo by co-transfecting the appro-
priate plasmids into yeast. b-Galactosidase activity was then determined.
Nucleic Acids Research, 2005, Vol. 33, No. 16 5241and as such, would act effectively as an anti-Myc drug (29).
Indeed, this mutant dimer was subsequently shown to have
improved thermodynamic stability and form more stable
E-box complexes. Therefore, rather than titrating out Max
to abolish Myc function (29), Myc peptides that provide a
stronger dimerization interface could also theoretically be
used to dominantly interfere with the formation of Myc:Max
complexes. Obviously, this would only be applicable in a
cancer cell that contained wild-type Myc.
In summary, we have shown for the ﬁrst time a major
difference between the C-termini of vMyc and cMyc, since
vMyc can sustain greater truncations of the C-terminal LZ
before loss in biological activity. Furthermore, we show
that a single point mutation in helix 2 from vMyc can in
isolation positively contribute to the interaction with Max.
We therefore propose that this mutation provides a more
hydrophobic surface between the dimerization interfaces of
Myc and Max. Together with data showing the functional
signiﬁcance of a mutation in the transactivation domain (7),
these data highlight the importance of virally derived muta-
tions as examples of naturally occurring protein engineering.
ACKNOWLEDGEMENTS
WewishtothankTrevorLittlewoodforhelpandreagents.This
work was funded by Cancer Research UK and Association for
International Cancer Research. Funding to pay the Open
Access publication charges for this article was provided by
JISC.
Conflict of interest statement. None declared.
REFERENCES
1. Frame,M.C. (2004) Newest findings on the oldest oncogene; how
activated Src does it. J. Cell Sci., 117, 989–998.
2. McCubrey,J.A., Shelton,J.G., Steelman,L.S., Franklin,R.A.,
Sreevalsan,T. and McMahon,M. (2004) Effects of a conditionally active
v-ErbB and an EGF-R inhibitor on transformation of NIH-3T3 cells and
abrogationofcytokinedependencyofhematopoieticcells.Oncogene,23,
7810-7820.
3. Acquaviva,C., Salvat,C., Brockly,F., Bossis,G., Ferrara,P.,
Piechaczyk,M.P. and Jariel-Encontre,I. (2001) Cellular and vial Fos
proteins are degraded by different proteolyic systems. Oncogene, 20,
942–950.
4. Dai,T., Rubie,E., Franklin,C.C., Kraft,A., Gillespie,D.A., Avruch,J.,
Kyriakis,J.M. and Woodgett,J.R. (1995) Stress-activated protein kinases
binddirectlytothedeltadomainofc-Juninrestingcells:implicationsfor
repression of c-Jun function. Oncogene, 10, 849–855.
5. Kanei-Ishii,C., Nomura,T., Tanikawa,J., Ichikawa-Iwata,E. and Ishii,S.
(2001) Differential sensitivity of v-Myb and c-Myc to Wnt-1-induced
protein degradation. J. Biol. Chem., 279, 44582–44589.
6. Cole,M.D. and McMahon,S.B. (1999) The Myc oncoprotein: a critical
evaluation of transactivation and target gene regulation. Oncogene,
18, 2916–2924.
7. Gavine,P.R., Neil,J.C. and Crouch,D.H. (1999) Protein stabilization: a
common consequence of mutations in independently derived v-Myc
alleles. Oncogene, 18, 7552–7558.
8. Hoang,A.T., Lutterbach,B., Lewis,B.C., Yano,T., Chou,T.Y.,
Barrett,J.F.,Raffeld,M.,Hann,S.R.andDang,C.V.(1995)Alinkbetween
increasedtransformingactivityoflymphoma-derivedMycmutantalleles,
their defective regulation by p107, and altered phosphorylation of the
c-Myc transactivation domain. Mol. Cell. Biol., 15, 4031–4042.
9. Petropoulos,C.J., Givol,I. and Hughes,S.H. (1996) Comparative analysis
ofthestructureandfunctionofthechickenc-mycandv-mycgenes:v-myc
is a more potent inducer of cell proliferation and apoptosis than c-myc.
Oncogene, 12, 2611–2623.
10. Henriksson,M., Bakardjiev,A., Klein,G. and Luscher,B. (1993)
Phosphorylation sites mapping in the N-terminal domain of c-Myc
modulate its transforming potential. Oncogene, 8, 3199–3209.
11. Walther,N., Jansen,H., Trachmann,C. and Bister,K. (1986) Nucleotide
sequence of the CMII v-myc allele. Virology, 154, 219–223.
12. Lutterbach,B. and Hann,S.R. (1994) Hierarchical phosphorylation at
N-terminaltransformation-sensitivesitesinc-Mycproteinisregulatedby
mitogens and in mitosis. Mol. Cell. Biol., 14, 5510–5522.
13. Salghetti,S., Kim,S.Y. and Tansey,W.P. (1999) Destruction of Myc by
ubiquitin-mediated proteolysis: cancer-associated and transforming
mutations stabilize Myc. EMBO J., 18, 717–726.
14. Flinn,E.M., Busch,C.M. and Wright,A.P. (1998) Myc boxes, which are
conserved in myc family of proteins, are signals for protein degradation
via the proteasome. Mol. Cell. Biol., 18, 5961–5969.
15. Muhle-Goll,C., Nilges,M. and Pastore,A. (1995) The leucine zippers of
the HLH-LZ proteins Max and c-Myc preferentially form heterodimers.
Biochemistry, 34, 13554–13564.
16. Crouch,D.H., Gallagher,R., Goding,C.R., Neil,J.C. and Fulton,R. (1996)
Multiple phenotypes associated with Myc-induced transformation of
chick embryo fibroblasts can be dissociated by a basic region mutation.
Nucleic Acids Res., 24, 3216–3221.
17. La Rocca,S.A., Crouch,D.H. and Gillespie,D.A.F. (1994) c-Myc inhibits
myogenic differentiation and MyoD expression by a mechanism which
can be dissociated from cell-transformation. Oncogene, 9, 3499–3508.
18. Crouch,D.H., Lang,C. and Gillespie,D.A.F. (1990) The leucine zipper
domain of avian cMyc is required for transformation and autoregulation.
Oncogene, 5, 683–689.
19. Crouch,D.H., Fisher,F., Clark,W., Jayaraman,P.S., Goding,C.R. and
Gillespie,D.A.F. (1993) Gene-regulatory properties of Myc helix–loop–
helix/leucine zipper mutants: max-dependent DNA-binding and
transcriptional activation in yeast correlates with transforming
capacity. Oncogene, 8, 1849–1855.
20. Batchelor,C.L., Woodward,A.M. and Crouch,D.H. (2004) Nuclear ERM
(ezrin, radixin, moesin) proteins: regulation by cell density and nuclear
import. Exp. Cell Res., 296, 208–222.
21. Littlewood,T.D., Amati,B., Land,H. and Evan,G.I. (1992) Max and
c-Myc/Max DNA-binding activities in cell extracts. Oncogene, 7,
1783–1792.
22. Fisher,F., Jayaraman,P.-S. and Goding,C.R. (1991) c-Myc and the yeast
transcription factor PHO4 share a common CACGTG-binding motif.
Oncogene, 6, 1099–1104.
23. Jayaraman,P.-S.,Hirst,K.andGoding,C.R.(1994)Theactivationdomain
of a basic helix–loop–helix protein is masked by repressor interaction
with domains distinct from that required for transcription regulation.
EMBO J., 13, 2192–2199.
24. Fuerstenberg,S., Beug,H., Introna,M., Khazaie,K., Munoz,A., Ness.,S.,
Nordstrom,K., Sap,J., Stanley,I., Zenke,M. et al. (1990) Ectopic
expression of the erythrocyte band 3 anion exchange protein,
using a new avian retrovirus vector. J. Virol., 64, 5891–5902.
25. Lee,C.M. and Reddy,E.K. (1999) The v-myc oncogene. Oncogene, 18,
2997–3003.
26. Sollenberger,K.G., Kao,T.-L. and Taparowsky,E.J. (1994) Structural
analysis of the chicken max gene. Oncogene, 9, 661–664.
27. Luscher,B. and Larsson,L.-G. (1999) The basic region/helix–loop–helix
zipper domain of Myc proto-oncoproteins: function and regulation.
Oncogene, 18, 2955–2966.
28. Fisher,F., Crouch,D.H., Jayaraman,P.S., Clark,W., Gillespie,D.A.F. and
Goding,C.R. (1993) Transcription activation By Myc and Max: flanking
sequences target activation to a subset of CACGTG motifs in vivo.
EMBO J., 12, 5075–5082.
29. Jean-Francois,N., Frederic,G., Raymund,W., Benoit,C. and Lavigne,P.
(2003) Improving the thermodynamic stability of the leucine zipper
of Max increases the stability of its b-HLH-LZ:E:box complex.
J. Mol. Biol., 326, 1577–1595.
30. Sakamuro,D. and Prendergast,G.C. (1999) New Myc-interacting
proteins: a second Myc network emerges. Oncogene, 18, 2942–2954.
31. Nieddu,E., Melchiori,A., Pescarolo,M.P., Bagnasco,L., Biasotti,B.,
Licheri,B., Malacarne,D., Tortolina,L., Castagnino,N., Pasa,S. et al.
(2005) Sequence specific peptidomimetic molecules inhibitors of a
protein–protein interaction at the helix 1 level of c-Myc. FASEB J.,
19, 632–634.
5242 Nucleic Acids Research, 2005, Vol. 33, No. 16